vs
Side-by-side financial comparison of Hinge Health, Inc. (HNGE) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.
Orthofix Medical Inc. is the larger business by last-quarter revenue ($219.9M vs $154.2M, roughly 1.4× Hinge Health, Inc.). Orthofix Medical Inc. runs the higher net margin — -1.0% vs -1.2%, a 0.2% gap on every dollar of revenue. Hinge Health, Inc. produced more free cash flow last quarter ($82.3M vs $16.8M).
Hinge Health is a leading digital musculoskeletal care solution provider that delivers clinically validated programs combining exercise therapy, pain management, and one-on-one health coaching for employers, health plans, and individual users across North America and Europe, focused on reducing chronic musculoskeletal pain and improving long-term physical health outcomes.
Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.
HNGE vs OFIX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $219.9M |
| Net Profit | $-1.8M | $-2.2M |
| Gross Margin | 81.8% | 71.1% |
| Operating Margin | -4.0% | 0.2% |
| Net Margin | -1.2% | -1.0% |
| Revenue YoY | — | 2.0% |
| Net Profit YoY | — | 92.4% |
| EPS (diluted) | $-0.02 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $219.9M | ||
| Q3 25 | $154.2M | $205.6M | ||
| Q2 25 | $139.1M | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $215.7M | ||
| Q3 24 | — | $196.6M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $188.6M |
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-1.8M | $-22.8M | ||
| Q2 25 | $-575.7M | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | — | $-33.4M | ||
| Q1 24 | — | $-36.0M |
| Q4 25 | — | 71.1% | ||
| Q3 25 | 81.8% | 72.2% | ||
| Q2 25 | 70.3% | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | -4.0% | -8.3% | ||
| Q2 25 | -417.5% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
| Q4 25 | — | -1.0% | ||
| Q3 25 | -1.2% | -11.1% | ||
| Q2 25 | -413.8% | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | — | -13.9% | ||
| Q2 24 | — | -16.8% | ||
| Q1 24 | — | -19.1% |
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-0.02 | $-0.57 | ||
| Q2 25 | $-13.10 | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $480.0M | $82.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $208.0M | $450.0M |
| Total Assets | $769.8M | $850.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $82.0M | ||
| Q3 25 | $480.0M | $62.9M | ||
| Q2 25 | $413.3M | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
| Q4 25 | — | $450.0M | ||
| Q3 25 | $208.0M | $442.5M | ||
| Q2 25 | $173.8M | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | — | $503.1M | ||
| Q3 24 | — | $525.9M | ||
| Q2 24 | — | $546.0M | ||
| Q1 24 | — | $570.3M |
| Q4 25 | — | $850.6M | ||
| Q3 25 | $769.8M | $832.6M | ||
| Q2 25 | $693.7M | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | — | $893.3M | ||
| Q3 24 | — | $867.9M | ||
| Q2 24 | — | $882.0M | ||
| Q1 24 | — | $906.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $27.7M |
| Free Cash FlowOCF − Capex | $82.3M | $16.8M |
| FCF MarginFCF / Revenue | 53.4% | 7.6% |
| Capex IntensityCapex / Revenue | 0.0% | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.7M | ||
| Q3 25 | $82.4M | $12.4M | ||
| Q2 25 | $25.1M | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | — | $9.0M | ||
| Q1 24 | — | $-18.6M |
| Q4 25 | — | $16.8M | ||
| Q3 25 | $82.3M | $2.5M | ||
| Q2 25 | $24.9M | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
| Q4 25 | — | 7.6% | ||
| Q3 25 | 53.4% | 1.2% | ||
| Q2 25 | 17.9% | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | 0.0% | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HNGE
Segment breakdown not available.
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
